The Novel Technology:
The present technology provides a cell-based assay for identifying a compound that modulates store-operated, intracellular calcium levels in a cell using inositol 1,4,5-trisphosphate receptor (itpr) mutant cell lines which have abnormal levels of ionic calcium.
- To screen drugs which can alter intracellular calcium levels
- To identify drugs that could be of therapeutic value in diseases such as Alzheimer's, Severe Combined Immuno Deficiency (SCID), Dariers’ Diseases (DAR), acute pancreatitis (AP), Spino-Cerebellar Ataxias (SCA)
- Rapid screen for potential drug candidates for therapeutic uses
- Cells have modulated calcium ion release upon stimulation
The technology is currently at an early stage with proof of concept demonstrated in a laboratory environment. Looking for potential licensee(s) for further development of the technology.
Principal Investigator(s): Dr. Gaiti Hasan, NCBS
Invention ID: CMP-021
IP Status: US Patent Granted
Jurisdictions: United States (US)
For more details, please write to:
techtransfer @ ccamp.res.in